Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Phase I study of BRD4 inhibitor SYHA-1801 begins for advanced solid tumors

May 12, 2020

Enrollment underway for first-in-human study of BRAF inhibitor ABM-1310 in advanced solid tumors

May 12, 2020

Dual adenosine A2A/A2B receptor antagonists described by Merck KGaA

May 12, 2020

Wild-type and mutant RET inhibitors identified at Medshine Discovery

May 12, 2020

Dana-Farber Cancer Institute, Voronoi patent wild-type and mutant LRRK2 inhibitors

May 12, 2020

New histone-lysine N-methyltransferase SMYD3 inhibitors identified at Epizyme

May 12, 2020

Array BioPharma discloses new PTPN11 inhibitors

May 12, 2020

Novel peptide-targeted approach improves potency of anticancer drugs

May 12, 2020

FDA approves Lynparza with bevacizumab for HRD-positive advanced ovarian cancer

May 11, 2020

Oncoinvent recruits for phase I study of Radspherin

May 11, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...